Determinants of Last-line Treatment in Metastatic Breast Cancer

Marika Cinausero, Lorenzo Gerratana, Elisa De Carlo, Donatella Iacono, Marta Bonotto, Valentina Fanotto, Vanessa Buoro, Debora Basile, Maria Grazia Vitale, Karim Rihawi, Gianpiero Fasola, Fabio Puglisi

Research output: Contribution to journalArticle

Abstract

Background: In metastatic breast cancer (MBC) patients, the identification of factors helping clinicians in the choice between active therapy versus best supportive care is needed clinically. The aim of the present study was to identify the clinicopathologic factors that could improve the prognostic valuation of MBC patients and clinical decision-making at the end of life. Patients and Methods: The present study analyzed data from a retrospective series of 522 MBC patients treated at the oncology department (University Hospital of Udine) from January 2004 to June 2014. The association between clinicopathologic features and death within 30 or 90 days since last-line treatment prescription was explored. Differences between lightly (≤ 3 lines) and heavily (> 3 lines) pretreated patients and the factors affecting treatment choice were investigated. Results: The event "death" occurred in 410 patients. The median last-line survival was 100 days. The median number of therapeutic lines was 3. On multivariate analysis, worse Eastern Cooperative Oncology Group performance status was significantly associated with death within 90 and 30 days since last-line treatment prescription. Among the heavily pretreated patients, liver function impairment and evaluation by a breast cancer specialist were significantly associated with a greater and lower risk of death within 30 days, respectively. Among the lightly pretreated patients with luminal disease, age < 70 years, luminal B-like disease, and number of previous lines were associated with a greater chance of receiving chemotherapy. Conclusion: In the present study, the Eastern Cooperative Oncology Group performance status was the most robust independent factor driving the last-line therapeutic choice for MBC patients. In addition, the molecular subtype and oncologist subspecialization also influenced the decision-making process.

Original languageEnglish
JournalClinical Breast Cancer
DOIs
Publication statusAccepted/In press - Jan 1 2017

Fingerprint

Breast Neoplasms
Therapeutics
Prescriptions
Decision Making
Multivariate Analysis
Drug Therapy
Survival
Liver

Keywords

  • Decision making
  • End of life
  • Last line treatment
  • MBC
  • Treatment outcomes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cinausero, M., Gerratana, L., De Carlo, E., Iacono, D., Bonotto, M., Fanotto, V., ... Puglisi, F. (Accepted/In press). Determinants of Last-line Treatment in Metastatic Breast Cancer. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2017.07.008

Determinants of Last-line Treatment in Metastatic Breast Cancer. / Cinausero, Marika; Gerratana, Lorenzo; De Carlo, Elisa; Iacono, Donatella; Bonotto, Marta; Fanotto, Valentina; Buoro, Vanessa; Basile, Debora; Vitale, Maria Grazia; Rihawi, Karim; Fasola, Gianpiero; Puglisi, Fabio.

In: Clinical Breast Cancer, 01.01.2017.

Research output: Contribution to journalArticle

Cinausero, M, Gerratana, L, De Carlo, E, Iacono, D, Bonotto, M, Fanotto, V, Buoro, V, Basile, D, Vitale, MG, Rihawi, K, Fasola, G & Puglisi, F 2017, 'Determinants of Last-line Treatment in Metastatic Breast Cancer', Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2017.07.008
Cinausero M, Gerratana L, De Carlo E, Iacono D, Bonotto M, Fanotto V et al. Determinants of Last-line Treatment in Metastatic Breast Cancer. Clinical Breast Cancer. 2017 Jan 1. https://doi.org/10.1016/j.clbc.2017.07.008
Cinausero, Marika ; Gerratana, Lorenzo ; De Carlo, Elisa ; Iacono, Donatella ; Bonotto, Marta ; Fanotto, Valentina ; Buoro, Vanessa ; Basile, Debora ; Vitale, Maria Grazia ; Rihawi, Karim ; Fasola, Gianpiero ; Puglisi, Fabio. / Determinants of Last-line Treatment in Metastatic Breast Cancer. In: Clinical Breast Cancer. 2017.
@article{edec24b80a784b6ea6ef383033b092c0,
title = "Determinants of Last-line Treatment in Metastatic Breast Cancer",
abstract = "Background: In metastatic breast cancer (MBC) patients, the identification of factors helping clinicians in the choice between active therapy versus best supportive care is needed clinically. The aim of the present study was to identify the clinicopathologic factors that could improve the prognostic valuation of MBC patients and clinical decision-making at the end of life. Patients and Methods: The present study analyzed data from a retrospective series of 522 MBC patients treated at the oncology department (University Hospital of Udine) from January 2004 to June 2014. The association between clinicopathologic features and death within 30 or 90 days since last-line treatment prescription was explored. Differences between lightly (≤ 3 lines) and heavily (> 3 lines) pretreated patients and the factors affecting treatment choice were investigated. Results: The event {"}death{"} occurred in 410 patients. The median last-line survival was 100 days. The median number of therapeutic lines was 3. On multivariate analysis, worse Eastern Cooperative Oncology Group performance status was significantly associated with death within 90 and 30 days since last-line treatment prescription. Among the heavily pretreated patients, liver function impairment and evaluation by a breast cancer specialist were significantly associated with a greater and lower risk of death within 30 days, respectively. Among the lightly pretreated patients with luminal disease, age < 70 years, luminal B-like disease, and number of previous lines were associated with a greater chance of receiving chemotherapy. Conclusion: In the present study, the Eastern Cooperative Oncology Group performance status was the most robust independent factor driving the last-line therapeutic choice for MBC patients. In addition, the molecular subtype and oncologist subspecialization also influenced the decision-making process.",
keywords = "Decision making, End of life, Last line treatment, MBC, Treatment outcomes",
author = "Marika Cinausero and Lorenzo Gerratana and {De Carlo}, Elisa and Donatella Iacono and Marta Bonotto and Valentina Fanotto and Vanessa Buoro and Debora Basile and Vitale, {Maria Grazia} and Karim Rihawi and Gianpiero Fasola and Fabio Puglisi",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.clbc.2017.07.008",
language = "English",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",

}

TY - JOUR

T1 - Determinants of Last-line Treatment in Metastatic Breast Cancer

AU - Cinausero, Marika

AU - Gerratana, Lorenzo

AU - De Carlo, Elisa

AU - Iacono, Donatella

AU - Bonotto, Marta

AU - Fanotto, Valentina

AU - Buoro, Vanessa

AU - Basile, Debora

AU - Vitale, Maria Grazia

AU - Rihawi, Karim

AU - Fasola, Gianpiero

AU - Puglisi, Fabio

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: In metastatic breast cancer (MBC) patients, the identification of factors helping clinicians in the choice between active therapy versus best supportive care is needed clinically. The aim of the present study was to identify the clinicopathologic factors that could improve the prognostic valuation of MBC patients and clinical decision-making at the end of life. Patients and Methods: The present study analyzed data from a retrospective series of 522 MBC patients treated at the oncology department (University Hospital of Udine) from January 2004 to June 2014. The association between clinicopathologic features and death within 30 or 90 days since last-line treatment prescription was explored. Differences between lightly (≤ 3 lines) and heavily (> 3 lines) pretreated patients and the factors affecting treatment choice were investigated. Results: The event "death" occurred in 410 patients. The median last-line survival was 100 days. The median number of therapeutic lines was 3. On multivariate analysis, worse Eastern Cooperative Oncology Group performance status was significantly associated with death within 90 and 30 days since last-line treatment prescription. Among the heavily pretreated patients, liver function impairment and evaluation by a breast cancer specialist were significantly associated with a greater and lower risk of death within 30 days, respectively. Among the lightly pretreated patients with luminal disease, age < 70 years, luminal B-like disease, and number of previous lines were associated with a greater chance of receiving chemotherapy. Conclusion: In the present study, the Eastern Cooperative Oncology Group performance status was the most robust independent factor driving the last-line therapeutic choice for MBC patients. In addition, the molecular subtype and oncologist subspecialization also influenced the decision-making process.

AB - Background: In metastatic breast cancer (MBC) patients, the identification of factors helping clinicians in the choice between active therapy versus best supportive care is needed clinically. The aim of the present study was to identify the clinicopathologic factors that could improve the prognostic valuation of MBC patients and clinical decision-making at the end of life. Patients and Methods: The present study analyzed data from a retrospective series of 522 MBC patients treated at the oncology department (University Hospital of Udine) from January 2004 to June 2014. The association between clinicopathologic features and death within 30 or 90 days since last-line treatment prescription was explored. Differences between lightly (≤ 3 lines) and heavily (> 3 lines) pretreated patients and the factors affecting treatment choice were investigated. Results: The event "death" occurred in 410 patients. The median last-line survival was 100 days. The median number of therapeutic lines was 3. On multivariate analysis, worse Eastern Cooperative Oncology Group performance status was significantly associated with death within 90 and 30 days since last-line treatment prescription. Among the heavily pretreated patients, liver function impairment and evaluation by a breast cancer specialist were significantly associated with a greater and lower risk of death within 30 days, respectively. Among the lightly pretreated patients with luminal disease, age < 70 years, luminal B-like disease, and number of previous lines were associated with a greater chance of receiving chemotherapy. Conclusion: In the present study, the Eastern Cooperative Oncology Group performance status was the most robust independent factor driving the last-line therapeutic choice for MBC patients. In addition, the molecular subtype and oncologist subspecialization also influenced the decision-making process.

KW - Decision making

KW - End of life

KW - Last line treatment

KW - MBC

KW - Treatment outcomes

UR - http://www.scopus.com/inward/record.url?scp=85028075063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028075063&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2017.07.008

DO - 10.1016/j.clbc.2017.07.008

M3 - Article

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

ER -